ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 091,86
-0,17%
Dow Jones
38 460,92
-0,11%
DAX
18 077,71
-0,36%
Brent Oil
87,225
0,01%
Bitcoin
64 280,55
0,00%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. L'Europe
  5. EU
  6. Argen X SE (ARGX)

  7. Argen X SE (ARGX) Actualités

ARGX Argen X SE

349,90
0,70 (0,20%)
25 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Argen X SE ARGX Euronext Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,70 0,20% 349,90 03:01:02
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
351,00 348,50 356,40 349,90 349,20
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
16/4/202407:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
27/3/202407:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
26/3/202421:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26/3/202407:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
07/3/202422:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
29/2/202407:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
26/2/202407:00GLOBEargenx to Present at Upcoming Investor Conferences
22/2/202407:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
20/2/202407:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
18/1/202407:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
08/1/202407:00GLOBEargenx Highlights 2024 Strategic Priorities
02/1/202407:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
20/12/202307:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
28/11/202307:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
16/11/202313:40GLOBEargenx Announces European Commission Approval of..
01/11/202307:00GLOBEargenx Highlights Data Evaluating VYVGART in Neuromuscular..
31/10/202307:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
24/10/202307:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
21/9/202307:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
15/9/202307:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
30/8/202307:00GLOBEargenx to Present at Upcoming Investor Conferences
27/7/202307:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
24/7/202322:30GLOBEargenx announces closing of global offering
20/7/202307:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
19/7/202323:58GLOBEargenx announces full exercise of underwriters’ option to..
19/7/202303:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
17/7/202322:01GLOBEargenx announces launch of proposed global offering
17/7/202307:00GLOBEargenx Reports Positive Topline Data from ADHERE Study of..
30/6/202315:39GLOBEargenx and Zai Lab Announce Approval of VYVGART®..
21/6/202300:12GLOBEargenx Announces U.S. Food and Drug Administration Approval..
20/6/202307:00GLOBEargenx Initiates Second Cohort of Phase 2 ARDA Study of..
31/5/202307:00GLOBEargenx to Present at Upcoming Investor Conferences
04/5/202307:00GLOBEargenx Reports First Quarter 2023 Financial Results and..
03/5/202322:01GLOBEargenx announces results of Annual General Meeting of..
02/5/202307:00GLOBEargenx to Present at BofA Securities 2023 Health Care..
27/4/202307:00GLOBEargenx to Report First Quarter 2023 Financial Results and..

Dernières Valeurs Consultées

EU
ARGX
Argen X
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés